BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good afternoon, everyone. My name is Jess Fye, I'm a large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with BioCryst. A little bit of different format this year from years past. We're going to stay in this room for Q&A. If you have a question at the end of the presentation, just raise your hand, somebody you'll bring you a mic or you can submit them electronically as well.
So with that out of the way, let me turn it over to BioCryst's CEO, Jon Stonehouse.
Good afternoon. Thank you, Jess, for inviting us to this year's conference, and I was telling her before I got up here, I honestly can admit that I'm happy to be live in San Francisco. I didn't think I'd get to that point during COVID, but good to be here. I'm going to be making some forward-looking statements. Those statements have risks. The risk factors can be found in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
